Introduction: Patients with non-resectable biliary tract cancer have a poor prognosis even if treated with systemic chemotherapy. One hope for improving treatment is through molecular biology and the characterization of specific cancer driving alterations followed by the design of targeted drugs. The epidermal growth factor receptor system is upregulated in many cancers and can be targeted by the protein kinase inhibitor erlotinib. Erlotinib has demonstrated a clinically applicable effect in pancreatic and lung cancer Areas covered: In this review, the author presents the published clinical data about erlotinib in biliary tract cancer. The data is interpreted with respect to its clinical value and in regards to its future development.
Expert Opinion: Erlotinib has low activity as a monotherapy, but has shown synergistic effects when combined with bevacizumab. The only phase III trial with erlotinib was negative, but suggested improved progression free survival in cholangiocarcinoma patients when added to gemcitabine and oxaliplatin. There is no clinical, radiological or molecular marker to guide therapy, but genomic profiling and basket or umbrella trials may be useful in identifying the subset of patients benefitting from erlotinib. Until this subgroup has been defined, erlotinib has no value to biliary tract cancer patients in the daily clinic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/13543784.2016.1142973 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor-associated lymphatic vessel density is a postoperative prognostic biomarker of hepatobiliary cancers: a systematic review and meta-analysis.
Front Immunol
January 2025
Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Kunming Medical University, Kunming, China.
Purpose: This study aimed to investigate whether tumor-associated lymphatic vessel density (LVD) could predict the survival of patients with hepato-biliary-pancreatic (HBP) cancers after radical resection.
Methods: A systematic search was conducted using PubMed, Embase, and Cochrane Library from the inception to July 31, 2024 for literature that reported the role of LVD in overall survival (OS) and recurrence-free survival (RFS) of patients with HBP cancers after radical resection.
Results: Ten studies with 761 patients were included for the meta-analysis.
Deep Learning-assisted Diagnosis of Extrahepatic Common Bile Duct Obstruction Using MRCP Imaging and Clinical Parameters.
Curr Med Imaging
January 2025
Department of Electronic and Electrical Engineering, Ewha Womans University, Seoul 03760, South Korea.
Background: Extrahepatic Common Bile Duct Obstruction (EHBDO) is a serious condition that requires accurate diagnosis for effective treatment. Magnetic Resonance Cholangiopancreatography (MRCP) is a widely used noninvasive imaging technique for visualizing bile ducts, but its interpretation can be complex.
Objective: This study aimed to develop a deep learning-based classification model that integrates MRCP images and clinical parameters to assist radiologists in diagnosing EHBDO more accurately.
Robust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer.
BMC Med
January 2025
Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Background: A new circulating biomarker superior to carbohydrate antigen 19-9 (CA19-9) is needed for diagnosing pancreatobiliary cancer (PBca). The aim of this study was to identify serum microRNA (miRNA) signatures comprising reproducible and disease-related miRNAs.
Methods: This multicenter study involved patients with treatment-naïve PBca and healthy participants.
IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma.
Cancer Biother Radiopharm
January 2025
Department of Hepatobiliary Surgery, Jinshan District Central Hospital affiliated to Shanghai University of Medicine & Health Sciences, Shanghai, China.
Treatment options for patients with advanced biliary tract cancer (BTC) are limited. The programmed cell death protein-1 () inhibitors may have synergistic effects with chemotherapy. Therefore, the aim of our study was to provide real-world data on treatment outcomes in BTC patients receiving chemotherapy alone versus a combination of chemotherapy and inhibitors.
View Article and Find Full Text PDFEndoscopic retrograde cholangiopancreatography in children with pediatric congenital biliary dilatation associated with pancreatobiliary maljunction: experience from a tertiary center.
Front Pediatr
January 2025
Digestive Endoscopy and Surgery Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Background: Congenital biliary dilatation (CBD) is a congenital malformation of the main biliary tract usually associated with the pancreatobiliary maljunction (PBM), determining stone formation, cholangitis, pancreatitis, and cholangiocarcinoma. The role of endoscopic retrograde cholangiopancreatography (ERCP) in treatment and diagnosis has not been established yet. Therefore, the aim of our study is to define the actual role of ERCP in children with CBD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!